Clinical Trial Update: Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial results for Paclitaxel plus Bevacizumab, with or without Everolimus, in HER2-negative metastatic breast cancer have been completed and posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Afinitor (everolimus)
• Bevacizumab (bevacizumab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-12-22